|
SG183356A1
(en)
|
2010-02-18 |
2012-09-27 |
Univ California |
INTEGRIN aVß8 NEUTRALIZING ANTIBODY
|
|
JP2014510080A
(ja)
*
|
2011-03-09 |
2014-04-24 |
セントローズ， エルエルシー |
細胞外標的化薬物複合体
|
|
WO2013023162A2
(en)
*
|
2011-08-10 |
2013-02-14 |
Genus Oncology, Llc |
Anti-muc1 antibodies for cancer diagnostics
|
|
RU2614252C2
(ru)
*
|
2011-08-17 |
2017-03-24 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Антитела, которые связывают интегрин альфа-v бета-8
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN102786595B
(zh)
*
|
2012-08-03 |
2014-04-23 |
无锡傲锐东源生物科技有限公司 |
抗cd5蛋白单克隆抗体及其用途
|
|
EA031025B1
(ru)
|
2012-12-21 |
2018-11-30 |
Сиэтл Дженетикс, Инк. |
Антитела против ntb-a и связанные с ними композиции и способы
|
|
ES2871816T3
(es)
*
|
2012-12-27 |
2021-11-02 |
Sanofi Sa |
Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2015221388A1
(en)
*
|
2014-02-19 |
2016-08-04 |
Emergent Biosolutions Canada Inc. |
Methods of modulating an immune response
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
EP3286225B1
(en)
|
2015-04-23 |
2020-07-01 |
Baylor College of Medicine |
Cd5 chimeric antigen receptor for adoptive t cell therapy
|
|
WO2017214285A1
(en)
*
|
2016-06-07 |
2017-12-14 |
Eynav Klechevsky |
Detection of cd5 and methods and compositions for modulating cd5
|
|
US10316088B2
(en)
|
2016-06-28 |
2019-06-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
WO2018017864A2
(en)
*
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
|
BR112019005129A2
(pt)
*
|
2016-09-16 |
2019-06-04 |
Shanghai Henlius Biotech, Inc. |
anticorpos anti-pd-1
|
|
US20180128545A1
(en)
|
2016-11-08 |
2018-05-10 |
Berry Metal Company |
Modular furnace cooling wall
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
IL316155A
(en)
|
2017-11-29 |
2024-12-01 |
Heidelberg Pharma Res |
Compositions and Methods for the Depletion of CD5(PLUS) CELLS
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US11435351B2
(en)
*
|
2018-04-18 |
2022-09-06 |
Biomadison, Inc. |
Methods for determining vaccine potency
|
|
WO2020097193A1
(en)
|
2018-11-06 |
2020-05-14 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
EP3898692A4
(en)
|
2018-12-19 |
2022-10-19 |
The Trustees of the University of Pennsylvania |
USE OF CD2/5/7 KNOCK-OUT ANTI-CD2/5/7 CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST T-CELL LYMPHOMA AND LEUKEMIA
|
|
CN115605491A
(zh)
|
2019-04-05 |
2023-01-13 |
刘扶东（Us） |
抗唾液酸酶的糖类、其制造方法及用途
|
|
JP2022530026A
(ja)
|
2019-04-24 |
2022-06-27 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アマトキシン抗体薬物複合体及びその使用
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
CA3149897A1
(en)
|
2019-09-03 |
2021-03-11 |
Daniel Getts |
Methods and compositions for genomic integration
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
CA3182526A1
(en)
|
2020-05-08 |
2021-11-11 |
Academia Sinica |
Chimeric influenza vaccines
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
WO2021231982A1
(en)
*
|
2020-05-14 |
2021-11-18 |
City Of Hope |
Smc1a antibodies and uses thereof
|
|
EP3915641A1
(en)
*
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
|
EP4200335A4
(en)
*
|
2020-08-21 |
2024-10-02 |
City of Hope |
Anti-cd5 antibody compositions and uses thereof
|
|
US20240041932A1
(en)
|
2020-09-14 |
2024-02-08 |
Vor Biopharma Inc. |
Compositions and methods for cd5 modification
|
|
CA3197423A1
(en)
|
2020-11-04 |
2022-05-12 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
WO2022099090A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind tgfbrii
|
|
US20250179172A1
(en)
*
|
2020-12-17 |
2025-06-05 |
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
Cd5 antibody and use thereof
|
|
WO2022152185A1
(zh)
*
|
2021-01-12 |
2022-07-21 |
南京驯鹿医疗技术有限公司 |
靶向cd5的全人源抗体
|
|
WO2022169825A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
AU2022257113B2
(en)
|
2021-04-12 |
2024-07-18 |
Academia Sinica |
Improved coronavirus vaccine
|
|
US20240216428A1
(en)
*
|
2021-04-29 |
2024-07-04 |
Korea Research Institute Of Bioscience And Biotechnology |
Novel Anti-CD5 Chimeric Antigen Receptor and Immune Cell Expressing Same
|
|
IL308445A
(en)
|
2021-05-11 |
2024-01-01 |
Myeloid Therapeutics Inc |
Methods and compositions for genomic integration
|
|
CN113105547B
(zh)
*
|
2021-05-18 |
2022-04-08 |
福州迈新生物技术开发有限公司 |
抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
|
|
TW202334429A
(zh)
|
2021-10-01 |
2023-09-01 |
中央研究院 |
Sars-cov-2棘蛋白特異性抗體及其用途
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
US12077597B2
(en)
|
2021-11-24 |
2024-09-03 |
International-Drug-Development-Biotech |
Anti-CD5 antibodies and methods of use thereof
|
|
EP4457243A4
(en)
*
|
2021-12-27 |
2025-12-17 |
Academia Sinica |
ANTIBODIES AGAINST THE SPIKE PROTEIN OF SARS-CoV-2 AND USES THEREOF
|
|
WO2024039683A1
(en)
*
|
2022-08-15 |
2024-02-22 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
JP2025536873A
(ja)
|
2023-04-08 |
2025-11-12 |
ロック・バイオメディカル・インコーポレイテッド |
ポリマーソームによる標的化送達のための方法及び組成物
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258967A1
(en)
*
|
2023-06-13 |
2024-12-19 |
Synthis Therapeutics, Inc. |
Anti-cd5 antibodies and their uses
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|